



PROPOSED BUSINESS COMBINATION

# Nano Dimension + Infinite Epigenetics

Forming a publicly traded AI-powered company to  
redefine how chronic disease is predicted, detected and  
prevented with epigenetics.



## DISCLAIMER

# Forward-looking statements & disclaimer.

### Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding Nano Dimension's strategic plan, strategic alternatives review process, expectations on the timing, economics and success of the proposed business combination, beliefs regarding the future success and long-term growth opportunities of Infinite Epigenetics and the combined company, expectations for the structure of the proposed business combination, belief that deploying Nano's capital and publicly traded company platform into a high growth healthcare and data business offers a more compelling path to long-term value creation than continuing to scale within the advanced digital manufacturing sector, and all other statements other than statements of historical fact that address activities, events or developments that Nano Dimension intends, expects, projects, believes or anticipates will or may occur in the future. Forward-looking statements may be characterized by terminology such as "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "target," "endeavor," "seek," "predict," "intend," "strategy," "plan," "may," "could," "should," "will," "would," "continue," "likely," or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. Such statements are based on management's beliefs and assumptions made based on information currently available to management. These forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results and performance to be materially different from those expressed or implied in the forward-looking statements. Accordingly, the Company cautions shareholders that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. The forward-looking statements contained or implied in this communication are subject to other risks and uncertainties, including, but not limited to (i) the risk that Nano Dimension and Infinite Epigenetics are unable to negotiate and enter into a definitive agreement for the proposed combination; (ii) the risk that the conditions to the closing (including any necessary shareholder approvals) are not satisfied; (iii) uncertainties as to the timing of the consummation of the proposed combination and the ability of each of Nano Dimension and Infinite Epigenetics to consummate the proposed combination; (iv) effect of the announcement of the proposed combination on the ability of Nano Dimension and Infinite Epigenetics to continue to operate their respective businesses and retain and hire key personnel and to maintain favorable business relationships; (v) risks related to the failure or delay in obtaining required approvals from any governmental or regulatory entity necessary to consummate the proposed combination; (vi) changes in the exchange ratio that could cause Nano Dimension's shareholders and Infinite Epigenetics' stockholders to own more or less of the combined company than is currently anticipated; (vii) risks related to the market price of Nano Dimension's shares relative to the value suggested by the term sheet; (viii) unexpected costs, charges or expenses resulting from the proposed combination; (ix) the potential for the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the definitive agreement for the proposed combination and the other agreements entered into in connection therewith; (x) the possibility that holders of CVRs may never receive any proceeds therefrom; (xi) changes in demand for Nano Dimension's or Infinite Epigenetics' products and services; (xii) global market, political and economic conditions, and conditions in the countries in which Nano Dimension and Infinite Epigenetics operate; (xiii) the impact of changes in law and government regulations; (xiv) competition in the epigenetics health industry; (xv) the risk of litigation, including any proceedings that may be instituted against Nano Dimension or Infinite Epigenetics related to the proposed combination; (xvi) the impact of rapid technological change in the epigenetics health industry; and (xvii) those discussed under the heading "Risk Factors" in Nano Dimension's annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on March 31, 2026, and in any subsequent filings with the SEC.

Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this communication.

### Additional Information and Where to Find It

The Company has filed a preliminary proxy statement and intends to file a proxy statement and WHITE proxy card with the SEC in connection with its solicitation of proxies for an extraordinary general meeting of shareholders that will include, among other proposals, a proposal to approve on a non-binding advisory basis a resolution regarding the continuation of Nano Dimension's strategic alternatives review process including any related transaction approved by the Board (the "Extraordinary General Meeting"). THE COMPANY'S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND THE ACCOMPANYING WHITE PROXY CARD WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION.

Shareholders may obtain the proxy statement, any amendments or supplements to the proxy statement and other documents as and when filed by the Company with the SEC without charge from the SEC's website at [www.sec.gov](http://www.sec.gov).

This communication also relates to a proposed combination involving Nano Dimension and Infinite Epigenetics and may be deemed to be solicitation material in respect of the proposed combination. In connection with the proposed combination, Nano Dimension intends to file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 that will contain a proxy statement of Nano Dimension that will constitute a prospectus with respect to shares of Nano Dimension's stock to be issued in the proposed combination (the "Proxy Statement/Prospectus"). Nano Dimension may also file other documents with the SEC regarding the proposed combination. This document is not a substitute for the Proxy Statement/Prospectus or any other document which Nano Dimension may file with the SEC. INVESTORS AND SECURITYHOLDERS OF NANO DIMENSION AND INFINITE EPIGENETICS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED BY NANO DIMENSION WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED COMBINATION AND RELATED MATTERS. Nano Dimension shareholders and Infinite Epigenetics stockholders will also be able to obtain free copies of the Proxy Statement/Prospectus (when available) and other documents containing important information about Nano Dimension, Infinite Epigenetics and the proposed combination that will be filed with the SEC by Nano Dimension through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov). Copies of the documents filed with the SEC by Nano Dimension will also be available free of charge on Nano Dimension's website at <https://investors.nano-di.com/sec-filings-1/default.aspx> or by contacting Nano Dimension's investor relations department by email at [ir@nano-di.com](mailto:ir@nano-di.com).

### Participants in the Solicitation

The Company, the President, Chief Executive Officer and Director, David Stehlin, and each of its non-employee directors (namely, Robert Pons; Phillip Borenstein; Dr. Joshua Rosensweig and Andrew Sriubas) are deemed to be "participants" (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the solicitation of proxies from the Company's shareholders in connection with the matters to be considered at the Extraordinary General Meeting. Information about the compensation of our non-employee Directors is set forth in the sections titled "Director Compensation" and "Director Compensation Table" in the Company's Annual Report, at pages 54-56, and is available [here](#). Information about the compensation of our President, Chief Executive Officer, and Director, David Stehlin, is set forth in the section titled "Executive Compensation" in the Annual Report, at pages 56-64, and is available [here](#). Information regarding the participants' holdings of the Company's securities can be found in the section titled "Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters" in the Company's Annual Report on pages 64-65 and is available [here](#), and as updated in the filings referenced below. Supplemental information regarding the participants' holdings of the Company's securities can be found in SEC filings on Statements of Change in Ownership on Form 4 filed with the SEC on May 29, 2026 for Mr. Stehlin (available [here](#)) and June 12, 2026 (available [here](#)). Such filings are available on the Company's website at <https://investors.nano-di.com/sec-filings-1/default.aspx> or through the SEC's website via the links referenced above.


Updated information regarding the participants' direct or indirect interests, by security holdings or otherwise, is set forth in the Company's preliminary proxy statement on Schedule 14A and will be set forth in the Company's definitive proxy statement and other materials to be filed with the SEC in connection with the Extraordinary General Meeting.

Nano Dimension and its directors and executive officers may be deemed to be "participants" (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the solicitation of proxies from Nano Dimension's shareholders in connection with the proposed combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from Nano Dimension's shareholders in connection with the proposed combination will be set forth in the Proxy Statement/Prospectus on Form S-4 for the proposed combination, which is expected to be filed with the SEC by Nano Dimension. Investors and securityholders of Nano Dimension and Infinite Epigenetics are urged to read the Proxy Statement/Prospectus and other relevant documents that will be filed with the SEC by Nano Dimension carefully and in their entirety when they become available because they will contain important information about the proposed combination.

# Contents

04	Transaction Overview	19	Healthcare Provider Market Opportunity
07	What This Creates	20	Additional Market Opportunities
09	The Problem	21	Commercial Applications
11	Infinite Epigenetics Overview	22	Market Precedents
12	Why Now	23	The Infinite Portfolio
14	How The Test Works	24	Leadership
15	Our Proprietary Model	25	Our Partners
16	Our Data Flywheel	27	Our Investors
17	The Market Size	28	Key Takeaways
18	Performance vs. Existing Diagnostics	30	Reference Glossary

# Deploying capital into a high-growth healthcare AI opportunity.



The proposed transaction marks the culmination of Phase 3 of Nano Dimension's previously announced three-phase strategic plan, developed to maximize long-term shareholder value.

# Summary of potential opportunities review.

- Nano Dimension engaged Guggenheim Securities, LLC (“Guggenheim”) and Houlihan Lokey (“Houlihan”) to support the Nano Dimension’s Board of Directors in conducting a thorough and disciplined evaluation of a comprehensive range of strategic alternatives with the objective of maximizing shareholder value, including a review of its product lines, core technologies, market dynamics and competitive positioning.
- Guggenheim supported Nano Dimension in evaluating and executing opportunities to monetize its product lines.
- Houlihan supported Nano Dimension in evaluating a focused set of alternatives with respect to the Nano Dimension’s financial resources and public company platform.
- Possible alternatives included, a strategic merger, a reverse merger, or other strategic transactions intended to maximize shareholder value in 2026 and beyond.
- Nano Dimension identified multiple potential counterparties and actively engaged in discussions under a range of potential transaction structures.
- During the process, approximately 20 companies responded, 14 companies submitted indications of interest, of which several were interviewed, six face-to-face company meetings were conducted, and a smaller group of four companies were included in the short list of preferred companies in the process.
- Nano Dimension has conducted due diligence on Infinite with the assistance of multiple consultants in the healthcare space.
- The Nano Dimension Board of Directors approved the Infinite transaction term sheet.



NANODIMENSION

# Summary of key terms.

- Signed Term Sheet: June 15, 2026
- Definitive Agreement expected to be executed before July 31, 2026
- The combined company is expected to operate under the Infinite Epigenetics name and continue trading on the Nasdaq Capital Market under the proposed ticker symbol "IEAI"
- Key Terms:
  - *Stock-for-stock merger valuing Infinite Epigenetics at \$890 million*
  - *Exchange ratio determined based on the stated value for Nano Dimension shares that reflects a 20% premium to Nano Dimension's estimated net cash at closing*
  - *Existing Nano Dimension shareholders expected to retain meaningful minority ownership in the combined company*
- Management and Board of Directors Composition:
  - *Matt Dawson, current CEO of Infinite, will lead the combined company as CEO*
  - *Following the closing, the combined company Board of Directors would consist of seven members*
  - *Infinite Epigenetics shall have the right to designate up to 5 directors, including 3 independent directors*
  - *Infinite Epigenetics plans to nominate Brad Keywell, Matt Dawson, and Rocky (Raquel) Bono to the Board of Directors*
- Transaction subject to negotiation and execution of definitive agreement and will require a subsequent Nano Dimension Shareholder vote
  - *Transaction expected to close by the end of the year.*



WHAT THIS CREATES

# An AI-powered preventive health and diagnostics company on Nasdaq.

The proposed combination would bring Infinite Epigenetics, its proprietary biological AI platform and revenue-generating diagnostics operations, to the public market under the ticker IEAI.



## Commercial stage company

CLIA-certified lab; established sales org with 7,500+ providers in our network; live revenue today.



## Robust IP portfolio & dataset

11 patent families; one of the largest private DNA-methylation datasets globally.



## Proprietary biological AI model

An epigenetics-anchored foundation model that compounds with every test.



## Four lead disease programs

COPD, Type 2 Diabetes, Cardiovascular Disease, and MASLD (Fatty Liver) from one at-home blood test.



## Experienced leadership team

Co-founded by Dr. Matthew Dawson, Dr. Michael Mallin, and Brad Keywell, Original Investor & Board Member of Tempus AI (Nasdaq: TEM).




## Many channels, one engine

Current: Healthcare Providers, Research, Commercial, Consumer.  
Future: Employer & Enterprise, Medicare Advantage, Life Insurance, Pharma, Military.


EVERY 11 SECONDS

Someone in the world dies from COPD.




EVERY 9 SECONDS

Someone in the world dies of diabetes.



EVERY 2 SECONDS

Someone in the world dies of cardiovascular disease.



THE PROBLEM


# Chronic diseases cause ~75% of deaths worldwide.

Today's diagnostics are failing us. They are reactive, confirming disease after symptoms appear, often years after the biology has already changed. The cost of that delay is measured in trillions, and in countless lives.

>4 Billion

People worldwide live with one of these diseases.

- Type 2 Diabetes
- Cardiovascular Disease
- MASLD (Fatty Liver Disease)
- Chronic Obstructive Pulmonary Disease (COPD)



>7 Years

Average time from disease onset to diagnosis.



\$4.5T

Annual health care expenditures for chronic and mental health conditions.

\$500B

Saved by scaling proven interventions.


Sources: WHO, "Noncommunicable Diseases," 2025; CDC, "Fast Facts: Health and Economic Costs of Chronic Conditions," 2026; McKinsey Health Institute, "The Health of Nations: Stronger Health, Stronger Economies," 2026. Boers et al., "Global Burden of COPD Through 2050," 2023; Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators, "Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories," 2025; Younossi et al., "The Global Epidemiology of NASH," 2023; International Diabetes Federation, "IDF Diabetes Atlas," 2025. Gopalan et al., "Prevalence and Predictors of Delayed Clinical Diagnosis of Type 2 Diabetes," 2019; Manikat et al., "Peri-Complication Diagnosis of NAFLD," 2025; Larsson et al., "Impact of COPD Timing on Clinical and Economic Outcomes," 2019.

What if you could predict or diagnose these diseases with *remarkable precision*, years before symptoms arise?



# We built the platform that makes it possible.

Infinite's proprietary biological AI model is trained on the most information-dense biological signal that exists: the epigenome. Until AI, no one could interpret it at scale. Now, we can predict disease years earlier and more precisely than traditional diagnostics.







## WHY NOW





# For the first time, AI can interpret epigenetics *at scale*.

Two forces are arriving at once. Epigenetics has become a validated, dynamic readout of the body, and AI has become powerful and cheap enough to interpret it at scale. *Infinite sits at the intersection.*

## EPIGENETICS IS NO LONGER EXPERIMENTAL

-  Epigenetics is the science of gene expression, shaped by lifestyle, aging, stress, and environmental factors.
-  DNA is 20% of your health. Epigenetics is approximately 80%.
-  Supports earlier risk detection, before late-stage disease, enabling true prevention, not just detection.
-  50+ peer-reviewed studies and 80+ partnerships with top institutions have validated the science.

## ARTIFICIAL INTELLIGENCE & FALLING COMPUTE COSTS

-  AI is now powerful enough to make sense of vast health data.
-  The cost of AI compute has fallen 5x to 10x over the past several years.
-  Foundation model improves as its dataset grows with every test.
-  One of the world's largest DNA methylation databases used to train the foundation model.

ONE-LINER

We read the *operating system* of the body, and use AI to translate it into earlier diagnosis and better care.



HOW THE TEST WORKS

A simple at-home blood collection powers millions of health insights.

01



### At-Home Blood Collection

A small blood sample, collected at home or in clinic.

02



### Lab Processing

Our CLIA-certified lab reads 1M+ epigenetic signals from a single sample.

03



### AI Translation

Our foundation model translates the raw signals into clear health insights.

04



### Clinical Guidance

Risk and disease insights empower physician consults that are preventive and personalized.

1M+


Epigenetic signals read per sample.

Every test expands the dataset that trains the model

OUR PROPRIETARY MODEL

# How the proprietary AI model works.

Infinite Epigenetics pairs one of the world's largest epigenetic datasets with a biological AI foundation model trained on billions of data points, redefining how disease is predicted, detected, and prevented.



Methylation array: the lab test that reads methylation from a blood sample · Multi-omic: several layers of biological data combined into one model · CpG site: a spot on DNA where methylation is measured; the array reads ~1M per sample  
Illustrative of the indication menu read from a single methylation array. The billions of data points are derived from 120,000+ samples processed, each measuring between 200,000-1 million CpG sites.

OUR DATA FLYWHEEL

# Why it's *hard to replicate*.

Most diagnostics companies have an AI chatbot. We have a flywheel, with five years of patent filings, proprietary know-how, and a compounding data asset, widening the gap between us and any future competitor.

120K+

samples collected. Every one made the model smarter.

1,500+

algorithms built on biology no one else has access to.

1M+

biological signals per test. Standard labs read 50.

80+

research partnerships. The people who built this field are building it with us.


“The most valuable healthcare AI platforms will be built on *proprietary biological data.*”

**Brad Keywell**

Co-Founder, Infinite Epigenetics · Original Investor & Board Member, Tempus AI

THE COMPOUNDING LOOP


More valuable, and more defensible, at scale.



THE MARKET SIZE

# Starting with four large, *underdiagnosed populations*.

Our initial focus is on four large chronic disease markets where novel diagnostic technologies can drive the biggest impact, with a clear roadmap for future entry into additional disease markets beyond these four.



**Platform optionality.**

Beyond the four initial diseases, the same foundation model reads biological age, additional disease proxies, and new indications at near-zero incremental cost.


Biological age: the body's age from epigenetic signals, vs. years lived

Sources: COPD Foundation, "COPD Prevalence, Disease Burden Varies Significantly by State," 2025; Le et al., "Estimated Burden of MASLD in US Adults," 2025; Kaiser Permanente, "Many Adults May Be Unaware That They Have Liver Disease," 2025; American Lung Association, "COPD in Your State," 2026; CDC, "National Diabetes Statistics Report," 2026; CDC, "Heart Disease Facts," 2024. Ho et al., "Under- and over-diagnosis of COPD," 2019. Lamprecht B, et al. "Determinants of Underdiagnosis of COPD in National and International Surveys." Chest. 2015. CDC, "Diabetes in the US," 2026.

PERFORMANCE VS. EXISTING DIAGNOSTICS

# Strong performance versus standard tools across four major chronic diseases.

Across major chronic diseases, our models show AUCs (area under the ROC curve) of 0.85–0.96. AUC measures how well a model separates people with a condition from those without it: 0.50 is no better than chance, 1.00 is perfect discrimination.







**PUBLISHED COMPARATOR RANGES – SEPARATE COHORTS, NOT HEAD-TO-HEAD COMPARISONS**

MASLD (detect) 0.96 vs FIB-4 ~0.76-0.85 · CVD (predict) 0.85 vs PREVENT ~0.76-0.79 · T2D (predict) 0.92 vs FINDRISC ~0.75 · COPD (detect) 0.91 vs symptom-based case-finding ~0.70

AUC: how well a test separates people with a condition from those without (0.5 chance, 1.0 perfect) · ROC curve: the plot of true vs. false positives that AUC is derived from  
\*AUC = area under the ROC curve (disease-state discrimination). Comparator values are published literature estimates that vary by population, endpoint, and time horizon and require same-cohort confirmation before use.

HEALTHCARE PROVIDER MARKET OPPORTUNITY

# \$94B prevalence TAM today.

INDICATION	PREVALENCE TAM	WHAT WE DETECT
Type 2 Diabetes 	\$42.9B	5-year T2D risk in prediabetes and metabolic-risk adults.
Cardiovascular Disease 	\$22.3B	5-year ASCVD risk for intermediate-risk primary-prevention adults.
MASLD (Fatty Liver) 	\$20.9B	Blood-based stratification for ≥F2 liver fibrosis in metabolic-risk adults.
COPD 	\$7.8B	Pre-spirometric diagnostic aid for symptomatic, undiagnosed adults.
Total Addressable Market	\$94B	

ASCVD: atherosclerotic cardiovascular disease; the standard 10-year heart-risk category; Prevalence TAM is calculated as full US addressable population x ASP (Avg. Sales Price)

Source: Company estimates based on CDC, "Trends in the Prevalence of COPD," 2023; Ho et al., "Under- and Over-diagnosis of COPD," 2019; CDC, "Type 2 Diabetes," 2024; Unalp-Arida and Ruhl, "Prevalence of MASLD and Fibrosis Defined by Liver Elastography," 2025; NIH, "Diabetes Statistics," 2024; CDC, "Diabetes in the US," 2026. Vega, Wang and Grundy, "Prevalence and Significance of Risk Enhancing Biomarkers in the US Population at Intermediate Risk for Atherosclerotic Disease," 2022. US Census Bureau, "Exploring Age Groups in the 2020 Census," 2023.

## ADDITIONAL MARKET OPPORTUNITIES

# Near-zero incremental cost for new markets.

The same finger prick that catches diabetes early can also enrich a pharma trial and screen a military unit.

### Healthcare Providers

Clinicians already benefit from the AI-generated health insights from our tests, tracking patient health changes over time.

CURRENT MARKET

### DTC & Commercial Partnerships

Our consumer business grows brand engagement and our health dataset, while third party brands that white-label our tests drive incremental revenue.

CURRENT MARKET

### Research & Institutional

Collaborations with leading research institutions that help validate the science and steadily expand the underlying dataset.

CURRENT MARKET

### SaaS & Software

Software that helps turn complex methylation results into clear, usable insights that labs and health systems could license.

FUTURE MARKET

### Military & Gov't Health

A chance to bring earlier health insights to vulnerable service members and veterans, a large, well-funded system with urgent unmet needs in areas like mental health.

FUTURE MARKET

### At-Risk & Enterprise

Health plans and employers that pay for outcomes have a built-in reason to adopt earlier detection, since catching disease sooner can help lower the long-term cost of care.

FUTURE MARKET

### Life Insurance

Insurers and investors price longevity for a living; biological-age insights could help them do it more accurately, in a way that's distinct from traditional genetic testing.

FUTURE MARKET

### Pharma & Data

Drug developers increasingly rely on large biological datasets, and Infinite's testing and data could support their biomarker, trial, and partnership work.

FUTURE MARKET

# The possibilities of what we can learn are *infinite*.

Our proprietary biological AI model is designed to support earlier disease-risk detection, treatment-response modeling, biological-age measurement, and other applications on one shared model. Each test expands the dataset available for future model development.



Early disease detection  
Earlier risk detection, before  
late-stage disease.



Biological age &  
longevity  
Protocols for optimal  
healthspan



Treatment response  
Predict responders before  
trial-and-error



Mental health  
Neurocognitive and nervous  
system markers



Fertility & maternal  
Preconception, IVF,  
pregnancy, postpartum



Drug discovery &  
targets  
Signatures that reveal what  
to target



Trial enrichment  
Select patients by biology,  
not diagnosis code



The Foundation  
One biological foundation  
model, with a roadmap to  
multi-omic inputs

MARKET PRECEDENTS

# Three companies with multi billion-dollar validations. Infinite does all of it, from one platform.

Exact Sciences proved diagnostics can scale in the public market. GRAIL proved methylation works. Tempus proved data plus AI is a platform. Infinite Epigenetics is where all three converge.

Exact Sciences

PROVEN

Molecular diagnostics can scale in the public markets with a single chronic disease test.



Infinite Epigenetics has the same science across multiple chronic diseases.

GRAIL

PROVEN

Methylation can power multi-disease detection from blood.



Infinite Epigenetics owns one of the world's largest methylation datasets.

Tempus

PROVEN

Proprietary clinical data + AI is a public-market platform.



Infinite Epigenetics has built a proprietary biological AI platform trained on biology.

# One data engine, *multiple brands*.

Infinite Epigenetics powers clinical diagnostics and longevity solutions across its portfolio with one biological data engine. Every test that TruDiagnostic and Tally run expands the shared biological data asset, so the entire platform gets smarter, and more valuable, over time.

## OPERATING COMPANY · CLINICAL



A commercial diagnostics platform and methylation data engine, TruDiagnostic has collected 120,000+ epigenetic samples, supported 80+ research studies and trials with pharma and academic partners, and is validated by 50+ peer-reviewed publications.

120k+ SAMPLES

50+ PUBLICATIONS

80+ PARTNERSHIPS

## OPERATING COMPANY · CONSUMER



Co-founded by Dr. David Sinclair, a Harvard Medical School professor, Tally is a consumer longevity and biological-age testing company with 15+ peer-reviewed publications validating the science. Built for anyone trying to slow aging and improve healthspan.

TIME-seq

TALLYAGE™

15+ PUBLICATIONS

LEADERSHIP

# A team that has *done this before*.

Proven operators paired with the scientists who authored the field, with \$20B+ in combined exits behind the founding team.



CO-FOUNDER

Matt Dawson, MD  
Chief Executive Officer

- Six-time healthcare founder with multiple exits
- Author of two medical textbooks and dozens of book chapters
- National award for Innovation in Healthcare
- Sought-after speaker on precision medicine, AI in healthcare, and the future of diagnostics



CO-FOUNDER & CURRENT CHAIR

Brad Keywell  
Board Member

- EY World Entrepreneur of the Year
- Original Investor and Board Member of Tempus AI
- Raised \$4B+ in capital over the last decade
- Serial entrepreneur with multiple \$1B+ exits, including Groupon, Tempus AI, and Echo Global Logistics



CO-FOUNDER

Mike Mallin, MD  
Chief Science Officer

- Two-time successful healthcare founder
- Author of 35 peer-reviewed publications
- Renowned educator on genomics, longevity, and systems-based health

Founded 10+ companies

\$20B+ in total exits

Clinical physicians and educators


National awards for innovation

50+ peer-reviewed studies published

OUR PARTNERS

# Built with *leading institutions.*

Relationships span research collaborations, data-use agreements, and licensed IP across leading institutions.



HARVARD  
UNIVERSITY

 Mass General Brigham

Duke  
UNIVERSITY

 EMORY  
UNIVERSITY

Yale

  
JOHNS HOPKINS  
UNIVERSITY

PEER-REVIEWED STUDIES

DUAS & COLLABORATIONS

50+

80+

Stanford  
University

L'ORÉAL

Lilly

illumina®

<sup>uk</sup>biobank

S | R | W®

BLUEPRINT  
BRYAN JOHNSON

NOVOS

HAPPY AGING

OLAPLEX®

OUR PARTNERS

# Science, clinical, and governmental advisors.

SCIENTIFIC RESEARCH BOARD



Jessica Lasky-Su, PhD  
Harvard



Raghav Sehgal, PhD  
Yale



Michael Corley, PhD  
Cornell



Andrew Teschendorff, PhD  
Cambridge



Wanding Zhou, PhD  
Van Andel Institute

MILITARY & GOVERNMENTAL AFFAIRS



VADM (Ret.) Rocky Bono, MD  
Former CEO, Defense Health Agency



David Shulkin, MD  
9th Secretary, U.S. Veterans Affairs



Gen. (Ret.) Michael Garrett  
U.S. Army



Gen. (Ret.) Paul Funk  
U.S. Army



Gen. (Ret.) Ed Daly  
U.S. Army



MG (Ret.) Dennis LeMaster  
U.S. Army

CLINICAL ADVISORY BOARD



Helen Messier  
MD, PhD



Sanjeev Goel  
MD, FCFP (PC), CAFCI



Vincent C. Giampapa  
MD, FACS



Edwin Lee  
MD, FACE



Pamela W. Smith  
MD, MPH, MS



Joseph Raffaele  
MD



Darshan Shah  
MD



Marcos de Andrade  
MD, MBA



Jeffrey Gladden  
MD, FACC



Paul Savage  
MD, FACEP, FAARM

OUR INVESTORS

# The capital backing the platform.

A founder-aligned cap table spanning consumer, growth, and technology investors.



Brad Keywell

Co-Founder, Infinite Epigenetics · Original Investor and Board Member of Tempus AI



AI in healthcare will not be defined by chatbots alone. We believe the most valuable healthcare AI platforms will be built on proprietary biological data. Infinite Epigenetics has the opportunity to bring that platform logic to epigenetics, one of the most powerful and dynamic data layers in medicine.



Whitney Casey, Venture Partner & Co-Founder of Tally Health



We see epigenetics and longevity as one of the most compelling long-term opportunities in healthcare — with the potential to reshape how health is measured, managed, and optimized. Infinite, with TruDiagnostic and Tally Health, has the scientific depth, data infrastructure, and ambition to scale it.



Joe Craft

Investor · CEO, Alliance Resource Partners



The best investments I have ever made are the ones that are good business and good for people at the same time, and this is one of them. Infinite Epigenetics uses their proprietary algorithms and biological foundation model to not only diagnose serious disease but also predict it years before any symptom shows up. This is the kind of company I intend to help build for the long run.

# Why shareholders should support this transaction.

- 01 A proprietary biological AI foundation model**

Our foundation model reads more than a million signals per sample and supports many clinical applications: early detection, disease diagnosis, biological age, treatment response, and more, with a roadmap to multi-omic applications.
- 02 Proprietary IP & a vast dataset that can't be replicated**

120,000+ samples, 5 years of patent filings and proprietary probe know-how, 80+ research partnerships, and an advisory board that authored the field of epigenetics and methylation.
- 03 A live, revenue-generating diagnostics business today**

A CLIA-certified lab, established salesforce, network of 7,500+ healthcare providers, plus consumer, research and commercial partner revenue streams live now. The business is generating revenue and clinician trust now, not at some future milestone.
- 04 Clear use of capital to scale validation, data, and commercialization**

AUCs of approximately 0.85–0.96 across our four lead disease applications: COPD, diabetes, cardiovascular disease, and MASLD (Fatty Liver). Capital scales data, harmonization, and the benchmark to clinical grade, along with salesforce scale to support expansion into payor markets.



NASDAQ: NNDM → IEAI

THE THESIS, ONE LAST TIME

One proprietary AI platform.

Many clinical answers.

*A compounding biological data asset.*

## REFERENCE

# Glossary.

## ASCVD

Atherosclerotic cardiovascular disease — the standard clinical category used for 10-year heart-disease risk scoring.

## AUC

Area Under the Curve, a score for how well a test separates people who have a condition from those who do not. 0.5 is a coin flip, 1.0 is perfect, and above 0.7 is generally considered clinically useful.

## Biological Age

An estimate of how old the body actually is biologically, based on epigenetic signals, as opposed to chronological age measured in years.

## Biomarker

A measurable biological signal used to indicate health, disease risk, or how a patient is responding to treatment.

## CLIA-certified

Certified under the U.S. Clinical Laboratory Improvement Amendments — the federal standard a lab must meet to run diagnostic tests on patient samples.

## CpG site

A specific spot on DNA where a methylation tag can attach. The array reads roughly one million of these sites per sample.

## DNA Methylation

A chemical tag added to DNA that turns genes on or off. It is the specific epigenetic signal Infinite reads, measured across more than a million sites per sample.

## DUA

Data-use agreement — a contract governing how a partner's data may be accessed, shared, and used.

## Epigenetics

The layer of biological control that decides which genes are switched on or off. It changes over time with aging, disease, stress, diet, and medication, unlike DNA, which is fixed at birth.

## Epigenome

The full set of these on/off instructions across the body. Often described as the body's operating system, because it reflects what the body is doing right now.

## Foundation Model

A large AI model trained on broad data so it can be adapted to many specific tasks. Here, a model trained to understand the language of biology underpins many clinical applications.

## Healthspan

The number of years a person lives in good health, as distinct from total lifespan.

## MASLD / MASH

Metabolic-associated steatotic liver disease, and its advanced form steatohepatitis — the current names for fatty liver disease (formerly NAFLD / NASH).

## Methylation Array

The lab test that reads methylation across the genome from a small blood sample. It is the physical input that the AI then interprets.

## Methylation Probe / Probe Set

The proprietary tools and methods used to read methylation signals efficiently, reducing training cost and sharpening the signal.

## Multi-Omic

Combining several layers of biological data (such as genomics, epigenomics, and others) into a single model for a fuller picture of the body.

## ROC curve

Receiver Operating Characteristic curve — the plot of true vs. false positive rates from which a test's AUC is calculated.

## Term Sheet

A non-binding summary of the principal terms of a proposed deal (such as valuation, structure, and governance) that the parties intend to negotiate into a binding definitive agreement.